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Objective: To evaluate the clinical signiﬁcance of the combination of cancer antigen-125 (CA-125), hu-
man epididymis protein 4 (HE4), and progesterone for the identiﬁcation of ovarian masses in patients
with suspected early stage ovarian cancer (OC).
Materials and methods: This was a caseecontrol, single-center study of 225 women with a pelvic mass of
suspected ovarian origin, including 75 patients with Stage I/II OC and 150 controls. Diagnostic procedures
included pelvic and rectal examinations, transvaginal ultrasound, evaluation of CA-125 and HE4 levels
alone and in the Risk of Ovarian Malignancy Algorithm (ROMA), and a new algorithm combining ROMA
and progesterone.
Results: Median CA-125 and HE4 levels were signiﬁcantly higher in patients with OC compared with
womenwith benign ovarian tumors, irrespective of menopausal status. The highest median progesterone
levels occurred in premenopausal women with benign ovarian tumors, compared with premenopausal
women with OC with or without benign ovarian disease. The combination of ROMA and progesterone
was signiﬁcantly more accurate at detecting OC compared with ROMA or CA-125 or HE4 alone, but only
in premenopausal patients.
Conclusion: Different algorithms should be used for diagnosing OC, and the addition of progesterone
might improve the performance of ROMA for the diagnosis of pelvic masses in premenopausal women.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ovarian masses are regularly detected in many women who
then undergo evaluations to determine if these masses are malig-
nant. Imaging techniques and laboratory tests can help primary-
care physicians and gynecologists to determine the likelihood of
cancer and to decide if the patient should be referred to a gyne-
cologic oncologist. Women with ovarian cancer (OC) who are
treated by a gynecologic oncologist tend to have better outcomes
than those treated by general gynecologists or surgeons [1].
Transvaginal sonography is currently the most widely used
diagnostic tool for detecting and differentiating ovarian massesgical Oncology, Jagiellonian
and.
itynski).
bstetrics & Gynecology. Published[2,3]. Computed tomography (CT),magnetic resonance imaging, and
positron emission tomography can all be used in the determination
and diagnosis of an ovarian mass, and all play pivotal roles in the
staging, treatment selection, and follow-upof patientswithOC [4,5].
In addition to imaging techniques, laboratory tests are also used
extensively in the differential diagnosis and therapy follow-up of
patients with OC. The ﬁrst approved OC marker was the cancer
antigen-125 (CA-125), which is elevated in approximately 80% of
patients with OC. CA-125 has a sensitivity of 50% in women with
Stage I disease and up to 90% in patients with more advanced-stage
disease [6,7]. This biomarker is particularly accurate among post-
menopausal women, in whom the positive predictive value (PPV)
reaches 98%, compared with only 49% in premenopausal patients
[8]. However, CA-125 is nonspeciﬁc and can be elevated under
many other conditions, including benign gynecologic etiologies,
nongynecologic diseases, and other malignancies, such as breast or
endometrial cancers [9,10].by Elsevier Taiwan LLC. All rights reserved.
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recently shown to be a complementary marker to CA-125 for
differentiating between benign and malignant diseases in women
with an ovarian tumor or pelvic mass [11e13]. HE4 is an 11-kDa
protein that is a precursor to the epididymal secretory protein E4,
and is overexpressed in OC. Using both CA-125 and HE4 according
to the Risk of Ovarian Malignancy Algorithm (ROMA) increased
sensitivity and speciﬁcity compared with either marker alone
[14e16]. At a speciﬁcity of 75%, the ROMA cutoff value showed
sensitivities of 77e81% for premenopausal women and 90e92% for
postmenopausal women [16e20].
However, a panel of complementary biomarkers able to detect
early stage OC with satisfactory sensitivity and speciﬁcity is still
required. Early stage OC can be treated effectively by primary sur-
gery followed by chemotherapy, attaining an 80e90% survival rate,
whereas women with advanced disease have much poorer prog-
noses [21]. Novel biomarkers enabling early stage OC diagnosis will
thus markedly improve the clinical treatment of OC.
Evidence suggests that ovarian carcinogenesis is affected by
steroid hormones, primarily estrogens, and progesterone. Recent
data have indicated that estrogens favor neoplastic transformation
within the surface epithelium of the ovary, whereas high proges-
terone levels seem to protect against the development of OC
[22,23].
We therefore determined whether progesterone could act as a
subsidiarymarker to improve the diagnosis of early stage OC. In this
study, we evaluated the clinical signiﬁcance of ROMA combined
with progesterone levels for use as a diagnostic tool to differentiate
ovarian masses.
Materials and methods
This single-center caseecontrol study was approved by the
Institutional Review Board of Jagiellonian University, Krakow,
Poland. All patients provided written informed consent.
Patient population
The primary group comprised 1358 patients diagnosed with a
pelvic mass of suspected ovarian origin at the Gynecology and
Oncology Department between 2008 and 2012, and who were
scheduled for surgical intervention. Exclusion criteria were as fol-
lows: (1) OC Stage III/IV, (2) age < 18 years, (3) prior bilateral oo-
phorectomy, (4) pregnancy, (5) history of infertility, (6) chronic
liver or (7) renal insufﬁciency, (8) pulmonary cystic ﬁbrosis or
tuberculosis, and (9) hormone treatment. Borderline ovarian tu-
mors were considered cancers according to the International
Federation of Gynecology and Obstetrics ovarian tumor classiﬁca-
tion [24]. Menopause was deﬁned clinically as a lack of menstrua-
tion for 12 months or more. Every patient with early stage OC was
matched for age, age at menarche, parity, and menopausal status
with two control patients diagnosed with benign ovarian masses,
identiﬁed from among the primary group of patients (Figure 1).
Participant allocation was carried out using a computer-generated
list of random numbers to select control cases from each group of
eligible patients using a block size sequence. After applying the
exclusion criteria and randomization, 255 patients were selected
for the ﬁnal analysis.
Diagnostic procedures
After recording their medical histories, all patients underwent
bimanual pelvic examination, rectal examination by a gynecologic
oncology consultant, and ultrasound imaging to document the
presence of an ovarianmass. Ultrasonographywas performed usinga Voluson 730 Pro equipped with a 6.5-MHz transvaginal probe
(General Electric Medical Systems, Kretztechnik, Zipf, Austria). For
large tumors, a transabdominal scan was also performed using a
2e5-MHz (transabdominal) transducer (General Electric Medical
Systems). Chest X-ray and pelvoabdominal CT scanwere performed
in selected cases as a part of the preoperative work-up.
Blood analysis
Venous blood samples were analyzed to determine CA-125,
HE4, and progesterone levels. Blood samples were centrifuged
within 4 hours of collection; serum and plasma were collected and
dispensed into multiple 5 cm3 CryoTubes (Sigma-Aldrich Sp. z.o.o.
Poznan, Poland), and all samples were frozen to 80C. The blood
samples were only analyzed if the patient ultimately entered the
study. Serum CA-125 concentrations were measured using the Ar-
chitect CA 125II assay (Abbott Diagnostics, Wiesbaden, Germany)
and were expressed as units/milliliter (reference range < 35.0 U/
mL). Serum HE4 levels were determined using the Architect HE4
assay (Abbott Diagnostics) and were expressed as picomole/liter
(reference range < 90.0 pmol/L). Serum progesterone concentra-
tions in premenopausal patients were determined during the
secretory phase of the menstrual cycle (because of irregular periods
in some patients, progesterone samples were taken at least 20 days
from the last menstrual bleeding) using the AxSYM Progesterone
Assay (Abbott Diagnostics) based on microparticle enzyme immu-
noassay technology, and reported in nanogram/milliliter. In post-
menopausal patients, progesterone levels were checked in the
same blood sample collected for evaluating CA-125 and HE4 levels.
The reference level of serum progesterone in the secretory phase of
the menstrual cycle was 5.5e38.0 ng/mL, and the postmenopausal
reference range was 0.5e1.0 ng/mL, according to the manufac-
turer's guidelines. The median time between blood sampling for
CA125, HE4, and progesterone and surgery was 17.5 days [inter-
quartile range (IQR) 6.0 days].
ROMA
ROMA is used to assess the risk of epithelial OC in patients with
an adnexal mass scheduled for surgical intervention. ROMA clas-
siﬁes patients into low- and high-risk groups for malignant disease
using algorithms, as described previously [15,16].
ROMA plus progesterone
We also assessed the risk of OC based on ROMA plus proges-
terone level. The progesterone concentration was coded as a
dichotomous value (i.e., within vs. below normal range). If ROMA
indicated a low risk of OC, the patient was described as a low-risk
case regardless of the progesterone level. If ROMA indicated a
high risk of OC but the progesterone level was within the normal
range (premenopausal, 5.5e38.0 ng/mL; postmenopausal,
0.5e1.0 ng/mL), then this case was also coded as having low risk.
However, if ROMA indicated a high risk of OC and the progesterone
level was below the normal range (i.e., <5.5 ng/mL for premeno-
pausal or <0.5 ng/mL for postmenopausal women), the patient was
described as a high-risk case.
Surgical treatment
All patients underwent routine surgical treatment, including
laparoscopic ovarian cyst enucleation and laparoscopic unilateral
adnexectomy or abdominal hysterectomy with bilateral adnex-
ectomy. In all 75 cases of OC, abdominal hysterectomywith bilateral
adnexectomy was followed by a full staging procedure [1,25].
Figure 1. Flow diagram demonstrating the patient-recruitment procedure. ROMA ¼ Risk of Ovarian Malignancy Algorithm.
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All specimens were examined by hematoxylineeosin staining
and immunohistochemistry, if required. The postoperative diag-
nosis was based on the ﬁnal histopathological report. In selected
cases, an intraoperative histopathological examination was per-
formed at the surgeon's discretion by a clinical pathologyconsultant, based on provided frozen sections. However, these re-
sults were for clinical use only and were not analyzed further.
Statistical analysis
Distributions of clinical variables were analyzed using Student t
test or the ManneWhitney U test and the results are presented as
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ences in median levels of markers among more than two groups
were evaluated using KruskaleWallis analysis of variance. Fisher
exact test (with Yates correction) was used to compare coded clin-
ical data. Diagnostic accuracy, test sensitivity, speciﬁcity, PPVs, and
negative predictive values (NPVs) were estimated for the entire
group of patients and separately for premenopausal and post-
menopausal women. A p value of 0.05 or less was deemed to be
statistically signiﬁcant. All calculations were performed using STA-
TISTICA data analysis software, version 9.0 (StatSoft, Tulsa, OK, USA).Results
The study enrolled 225 patients with adnexal masses, including
162 (72%) postmenopausal and 63 (28%) premenopausal women.
Overall, 150 patients (66.67%) had benign ovarian neoplasms and
75 (33.33%) had OC, including 58 Stage IAeIC and 17 Stage IIA cases.
Because the OC cases and controls were matched, median age,
median age at ﬁrst period, parity, and menopausal status did not
differ signiﬁcantly between women with benign tumors and those
with malignant tumors. The mean age of the patients with OC was
54.8 ± 10.71 years, mean age at ﬁrst period was 11.6 ± 2.1 years,
median age at last period was 52.3 ± 4.8 years, and median parity
was 1.0 (IQR 1.5). The respective values in the control group were
55.4 ± 10.9 years, 12.2 ± 2.8 years, 51.5 ± 5.8 years, and 1.5 (IQR 2.0).
The most common benign neoplasm was endometrial cyst, and
the predominant diagnosis in patients with malignant disease was
serous cystadenocarcinoma (Table 1).
The levels of tumor markers differed signiﬁcantly between
women with benign masses and those diagnosed with OC, in both
overall study group and premenopausal and postmenopausal
women separately. The median CA-125 concentration was signiﬁ-
cantly higher in women with OC than in women with benign
ovarian tumors [145.7 U/mL (IQR 283.30 U/mL) vs. 13.00 U/mL (IQR
27.00 U/mL), respectively; p < 0.001]. The median HE4 level was
also signiﬁcantly higher in patients with OC than in those with
benign ovarian masses [123.50 pg/mL (IQR 283.30 pg/mL) vs.
42.10 pg/mL (IQR 19.80 pg/mL), respectively; p < 0.001]. By
contrast, patients with OC had signiﬁcantly lower median proges-
terone levels compared with those with benign ovarian tumors
[0.35 ng/mL (IQR 0.68 ng/mL) vs. 0.47 ng/mL (IQR 0.68 ng/mL),
respectively; p < 0.013].
CA-125, HE4, and progesterone concentrations were further
analyzed after stratifying the patients with OC and benign ovarianTable 1
Histological classiﬁcation and distribution of ovarian masses [24].
Malignant n % Benign n %
1 Ovarian carcinoma 1 Endometrioma 61 40.67
Serous 31 41.34 2 Serous
cystadenoma/
cystadenoﬁbroma
29 19.34
Endometrioid 16 21.33
Mucinous 12 16.00
Clear cell 3 4.00 3 Mucinous
cystadenoma/
cystadenoﬁbroma
15 10.00
Undifferentiated 2 2.67
Carcinosarcoma 2 2.67
Mixed 1 1.33 4 Mature teratoma 20 13.33
2 Borderline ovarian
tumors
5 Brenner tumors 2 1.33
Serous 4 5.34 6 Functional cyst
(corpus luteum,
hemorrhagic cyst)
9 6.00
Mucinous 1 1.33
Endometrioid 1 1.33
3 Sex-cord stromal
tumors
1 1.33 7 Fibroma/
ﬁbrothecoma
14 9.33
4 Germ cell tumors 1 1.33
5 Metastatic tumors 0 0
Total 75 100 Total 150 100disease according to menopausal status. The highest median CA-
125 concentrations were observed in premenopausal and post-
menopausal women with OC [280.30 U/mL (IQR 359.40 U/mL) and
117.75 U/mL (IQR 510.80 U/mL), respectively] compared with pre-
menopausal women with benign ovarian tumors [19.95 U/mL (IQR
39.00 U/mL)] and postmenopausal women with benign ovarian
masses, who had the lowest median CA-125 values [12.80 U/mL
(IQR 12.70 U/mL)] (p < 0.001) (Figure 2).
The highest median HE4 levels were conﬁrmed in post-
menopausal patients with OC [145.85 pg/mL (IQR 311.00 pg/mL)],
followed by premenopausal women with OC [119.20 pg/mL (IQR
42.50 pg/mL)], postmenopausal women with benign ovarian dis-
ease [43.70 pg/mL (IQR 19.80 pg/mL)], and premenopausal patients
with benign ovarian disease [37.20 pg/mL (IQR 13.00 pg/mL]
(p < 0.001) (Figure 3).
By contrast, the median progesterone level was signiﬁcantly
higher in premenopausal women with benign ovarian tumors
[10.22 ng/mL (IQR 9.37 ng/mL)] compared with premenopausal
patients with OC [0.68 ng/mL (IQR 0.83 ng/mL)], postmenopausal
women with OC [0.35 ng/mL (IQR 0.65 ng/mL)], and post-
menopausal patients with benign ovarian tumors [0.44 ng/mL (IQR
0.55 ng/mL)] (p < 00.1) (Figure 4).
The ROMA uses both CA-125 and HE4 levels to calculate the risk
of OC. In this study, we determined whether adding the proges-
terone level to ROMA would improve the ﬁnal diagnostic accuracy.
In the overall study group, ROMA þ progesterone showed signiﬁ-
cantly lower sensitivity (0.640 vs. 0.867) and NPV (0.843 vs. 0.932)
comparedwith ROMA alone, but slightly better speciﬁcity (0.967 vs.
0.907) and PPV (0.906 vs. 0.823). However, ROMA þ progesterone
signiﬁcantly outperformed ROMA alone in premenopausal women,
showing higher speciﬁcity (0.976 vs. 0.769) and NPV (0.976 vs.
0.973), and comparable sensitivity and PPV (0.952 vs. 0.985 and
0.976 vs. 0.973, respectively). In postmenopausal women, ROMA
alone was signiﬁcantly better than the combined method
(ROMA þ progesterone vs. ROMA; sensitivity 0.519 vs. 0.833;
speciﬁcity 0.963 vs. 0.926; PPV 0.875 vs. 0.849; NPV 0.800 vs. 0.917).
ROMA þ progesterone thus had only slightly higher speciﬁcity and
NPV than ROMA alone, with signiﬁcantly poorer sensitivity and PPV
(Table 2).
Discussion
This was the ﬁrst study to assess the value of including pro-
gesterone level in an algorithm for differentiating early stage OC.
Our results suggest that the use of progesterone as a marker for the
diagnosis of OC should be limited to women of reproductive age.
There was no beneﬁt in including progesterone for detecting OC in
postmenopausal women, and its addition might even decrease the
clinical value of ROMA.
An increasing number of studies had suggested that HE4 is su-
perior to CA-125 for distinguishing between benign and malignant
ovarian diseases [10,11,13,26,27]. Kondalsamy-Chennakesavan et al.
[28] suggested that HE4 in combination with CA-125 and patient
age improved the differential diagnosis of pelvic masses, particu-
larly in postmenopausal women. In addition, a recent meta-
analysis including patients with suspicious pelvic masses sug-
gested that adding HE4 to the diagnostic algorithm improved the
speciﬁcity and sensitivity of OC detection, particularly in post-
menopausal women [29,30]. Nevertheless, more detailed studies
revealed that neither CA-125 nor HE4 was a reliable biomarker for
the diagnosis of borderline ovarian tumors [31].
No detailed studies have investigated the role of progesterone in
detecting early stage OC. We therefore compared the diagnostic
values of progesterone level with ROMA and ROMA without
progesterone for differentiating early OC. OC is diagnosed
Figure 2. Median cancer antigen-125 (CA-125) concentration in the analyzed subgroup of patients according to ﬁnal diagnosis and menopausal status. * Statistically signiﬁcant.
IQR ¼ interquartile range; post-BT ¼ postmenopausal with benign tumor; post-OC ¼ postmenopausal with ovarian cancer; Pre-BT ¼ premenopausal with benign tumor; Pre-
OC ¼ premenopausal with ovarian cancer.
Figure 3. Median HE4 concentration in the analyzed subgroup of patients according to ﬁnal diagnosis and menopausal status. * Statistically signiﬁcant. HE4 ¼ human epididymis
protein 4; IQR ¼ interquartile range; post-BT ¼ postmenopausal with benign tumor; post-OC ¼ postmenopausal with ovarian cancer; Pre-BT ¼ premenopausal with benign tumor;
Pre-OC ¼ premenopausal with ovarian cancer.
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Figure 4. Median progesterone concentration in the analyzed subgroup of patients according to ﬁnal diagnosis and menopausal status. * Statistically signiﬁcant. IQR ¼ interquartile
range; post-BT ¼ postmenopausal with benign tumor; post-OC ¼ postmenopausal with ovarian cancer; Pre-BT ¼ premenopausal with benign tumor; Pre-OC¼ premenopausal with
ovarian cancer.
Table 2
Clinical value of the Risk of Ovarian Malignancy Algorithm (ROMA) plus progesterone compared with ROMA without progesterone for the diagnosis of ovarian cancer in the
overall study population and in premenopausal and postmenopausal patients separately.
ACC Sensitivity Speciﬁcity PPV NPV LRþ LRe DOR
ROMA
Total sample 0.839 0.867 0.907 0.823 0.932 9.323 0.147 63.576
Premenopausal 0.899 0.952 0.857 0.769 0.973 6.657 0.056 118.861
Postmenopausal 0.895 0.833 0.926 0.849 0.917 11.257 0.180 62.418
ROMA þ progesterone
Total sample 0.858 0.640 0.967 0.906 0.843 19.394 0.372 52.094
Premenopausal 0.968 0.952 0.976 0.952 0.976 39.667 0.049 806.556
Postmenopausal 0.815 0.519 0.963 0.875 0.800 14.027 0.499 28.083
ACC ¼ diagnostic accuracy; DOR ¼ diagnostic odds ratio; LRþ ¼ positive likelihood ratio; LR ¼ negative likelihood ratio; NPV ¼ negative predictive value; PPV ¼ positive
predictive value; ROMA ¼ Risk of Ovarian Malignancy Algorithm.
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showed better sensitivity and speciﬁcity for OC diagnosis in post-
menopausal patients compared with women of reproductive age
[14,27]. The NPV of progesterone for differentiating OC was highest
in premenopausal patients, which thus became the target popula-
tion. The addition of progesterone levels to ROMA reduced the
incidence of false-positive cases without affecting the sensitivity of
the test.
The main strength of this study was the fact that a ﬁnal histo-
logical diagnosis was obtained for every patient. However, this
could also be regarded as a limitation, because the model focused
on patients scheduled for surgery. Our study was therefore limited
to a strictly selected group of patients with Stage I and Stage II OC,
irrespective of tumor histological type or grading. The limited
number of cases (OC is usually recognized at an advanced stage)
meant that we were unable to analyze the results for serous,mucinous, and endometrial tumors separately, although HE4
secretion has been shown to be associated with OC histotype
[32e34]. However, the tumor histopathology was unknown when
the ovarian masses were diagnosed in these participants, and the
novel diagnostic algorithmwas therefore developed irrespective of
OC histology.
From a clinical perspective, the optimal point in the menstrual
cycle at which to measure progesterone levels to obtain the most
reliable results remains unknown. Furthermore, the effect of his-
tological subtype of OC on the diagnostic value of progesterone is
unclear. Future research on the usefulness of progesterone in OC
diagnostics should therefore focus on these issues in patients with
Stage I disease to improve the early diagnosis of OC. Moreover,
further studies are needed to compare the role of progesterone in
combination with imaging techniques, including the Risk of Ma-
lignancy Index, International Ovarian Tumor Analysis, and
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OC detection. Because this study was limited to early cases of OC,
the sample was also too small to perform a statistical analysis ac-
cording to OC histological subtype.
In conclusion, the results of this study suggest that different
algorithms for OC differentiation should be used in premenopausal
and postmenopausal patients with adnexal masses. Moreover,
while a combination of the tumor markers HE4, CA-125, and pro-
gesterone outperforms ROMA alone for the differential diagnosis of
pelvic masses in premenopausal women, the addition of proges-
terone to OC differentiation algorithms does not improve, and may
even confuse, well-established diagnostic procedures for post-
menopausal women.
Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this article.
References
[1] Chang HN, Kao LY, Ng KK, Wong SY, Chang TC. Perioperative blindness after
debulking surgery for ovarian cancer. Taiwan J Obstet Gynecol 2014;53:
112e4.
[2] Knafel A, Banas T, Nocun A, Wiechec M, Jach R, Ludwin A, et al. The pro-
spective external validation of International Ovarian Tumor Analysis (IOTA)
simple rules in the hands of level I and II examiners. Ultraschall Med 2015. in
press.
[3] Abdulrahman Jr GO, McKnight L, Lutchman Singh K. The Risk of Malignancy
Index (RMI) in women with adnexal masses in Wales. Taiwan J Obstet Gynecol
2014;53:376e81.
[4] Vargas HA, Barrett T, Sala E. MRI of ovarian masses. J Magn Reson Imaging
2013;37:265e81.
[5] Kim HJ, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, et al. Surgical outcome
prediction in patients with advanced ovarian cancer using computed to-
mography scans and intraoperative ﬁndings. Taiwan J Obstet Gynecol
2014;53:343e7.
[6] Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al.
A radioimmunoassay using a monoclonal antibody to monitor the course of
epithelial ovarian cancer. N Engl J Med 1983;309:883e7.
[7] Bast Jr RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor
markers: CA125 and beyond. Int J Gynecol Cancer 2005;15:274e81.
[8] Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, et al.
Interpretation of single and serial measures of HE4 and CA125 in asymp-
tomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers
Prev 2012;21:2087e94.
[9] Givens V, Mitchell GE, Harraway-Smith C, Reddy A, Maness DL. Diagnosis and
management of adnexal masses. Am Fam Physician 2009;80:815e20.
[10] Cho FN, Liu CB, Li JY, Chen SN, Yu KJ. Dramatic changes of CA 125 levels in a
pregnant woman with a degenerated subserosal myoma. Taiwan J Obstet
Gynecol 2012;51:117e8.
[11] Paek J, Lee SH, Yim GW, Lee M, Kim YJ, Nam EJ, et al. Prognostic signiﬁcance of
human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol
Reprod Biol 2011;158:338e42.
[12] Hellstr€om I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M,
McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian car-
cinoma. Cancer Res 2003;63:3695e700.
[13] Hellstrom I, Hellstrom KE. Two novel biomarkers, mesothelin and HE4, for
diagnosis of ovarian carcinoma. Expert Opin Med Diagn 2011;5:227e40.
[14] Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, et al.
The utility of human epididymal protein 4, cancer antigen 125, and risk formalignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol
Cancer 2012;22:238e44.
[15] Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum
human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer
diagnosis: a systematic review. J Clin Pathol 2013;66:273e81.
[16] Chudecka-Głaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta
2015;440:143e51.
[17] Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al.
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction
of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:
40e6.
[18] Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al.
Evaluation of the diagnostic accuracy of the Risk of Ovarian Malignancy Al-
gorithm in women with a pelvic mass. Obstet Gynecol 2011;118:280e8.
[19] Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and
CA125 for the detection of ovarian cancer from patients with various gyne-
cologic and non-gynecologic diseases. Clin Biochem 2011;44:884e8.
[20] Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use
of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol
2010;116:378e83.
[21] Bamias A, Karadimou A, Soupos N, Sotiropoulou M, Zagouri F, Haidopoulos D,
et al. Prognostic factors for early-stage epithelial ovarian cancer, treated with
adjuvant carboplatin/paclitaxel chemotherapy: a single institution experi-
ence. Gynecol Oncol 2011;123:37e42.
[22] Brosens JJ, Lam EW. Progesterone and FOXO1 signaling: harnessing cellular
senescence for the treatment of ovarian cancer. Cell Cycle 2013;12:1660e1.
[23] Oesterreich S, Edwards R, Vlad A. Progestins: pro-senescence therapy for
ovarian cancer? Cell Cycle 2013;12:1662e3.
[24] Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A,
Peregrin I, et al. International Federation of Gynecology and Obstetrics staging
classiﬁcation for cancer of the ovary, fallopian tube, and peritoneum: esti-
mation of survival in patients with node-positive epithelial ovarian cancer. Int
J Gynecol Cancer 2015;25:49e54.
[25] Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of
surgeon specialty on processes of care and outcomes for ovarian cancer pa-
tients. J Natl Cancer Inst 2006;98:172e80.
[26] Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential
markers that complement expression of CA125 in epithelial ovarian cancer.
Gynecol Oncol 2005;99:267e77.
[27] Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human
epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by
serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162e9.
[28] Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Australian Ovarian
Cancer Study Group, Obermair A. Differentiating stage 1 epithelial ovarian
cancer from benign ovarian tumours using a combination of tumour markers
HE4, CA125, and CEA and patient's age. Gynecol Oncol 2013;129:467e71.
[29] Li F, Tie R, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian ma-
lignancy algorithm excel human epididymis protein 4 and CA125 in pre-
dicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 2012;12:258.
[30] Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential
diagnosis between benign gynecologic disease and ovarian cancer: a sys-
tematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol
2013;167:81e5.
[31] Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, et al. Pre-
operative HE4 and ROMA values do not improve the CA125 diagnostic value
for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.
J Ovarian Res 2014;7:49.
[32] Kappelmayer J, Antal-Szalmas P, Nagy Jr B. Human epididymis protein 4 (HE4)
in laboratory medicine and an algorithm in renal disorders. Clin Chim Acta
2015;438:35e42.
[33] Ławicki S, Be˛dkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma
concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different
stages and sub-types of epithelial ovarian tumors. J Ovarian Res 2013;6:45.
[34] Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. The use of
HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian
endometrioma and epithelial ovarian cancer. J Ovarian Res 2013;6:44.
